License Development and Commercialization Agreements (Details) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Sep. 14, 2020 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| License Development And Commercialization Agreements [Abstract] | |||
| Upfront cash payment | $ 5,000 | ||
| Excercise option price amount | $ 3,000 | $ 89 | $ 7 |
| License agreement, description | In addition, the License Agreement provides for a one-time non-refundable option payments of $3,000 per Option Product ($9,000 in the aggregate), and up to $30,000 of milestone payments payable as follows: (i) $5,000 upon completion of the U.S. facility design, (ii) $5,000 upon completion of production of a specified amount of BioInk, and (iii) $5,000 for FDA marketing approval for each Covered Product (up to $20,000 in the aggregate). | ||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Upfront Cash payment. No definition available.
|
| X | ||||||||||
- Definition A description of the commitments for license agreements that have been executed but were not reported because they do not meet the conditions for recording a liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Value of stock issued as a result of the exercise of stock options. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|